<![CDATA[Genmab — August 2020]]>AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q2 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4363134-abbvie-inc-abbv-ceo-rick-gonzalez-on-q2-2020-results-earnings-call-transcript?part=single

]]>https://dev.proinvestor.com/forum/topic/451545/genmab-august-2020RSS for NodeTue, 09 Jun 2026 22:31:12 GMTSat, 01 Aug 2020 07:22:11 GMT60<![CDATA[Reply to Genmab — August 2020 on Mon, 31 Aug 2020 14:35:20 GMT]]>Jo i forhold til omsætningen i dag, så var slutauktionen
omkring 60000

]]>https://dev.proinvestor.com/forum/post/10231039https://dev.proinvestor.com/forum/post/10231039Mon, 31 Aug 2020 14:35:20 GMT<![CDATA[Reply to Genmab — August 2020 on Mon, 31 Aug 2020 13:50:33 GMT]]>Men hidtil er det ikke lykkedes at overbevise Jan om det geniale i ideen.

]]>https://dev.proinvestor.com/forum/post/10231036https://dev.proinvestor.com/forum/post/10231036Mon, 31 Aug 2020 13:50:33 GMT<![CDATA[Reply to Genmab — August 2020 on Mon, 31 Aug 2020 13:50:09 GMT]]>Well, mit forslag er at udstede fondsaktier på NYSE således at der bliver en større del af aktierne noteret derovre. Det kunne kombineres med et split så der kom samme aktiestørrelse på alle aktier.

]]>https://dev.proinvestor.com/forum/post/10231037https://dev.proinvestor.com/forum/post/10231037Mon, 31 Aug 2020 13:50:09 GMT<![CDATA[Reply to Genmab — August 2020 on Mon, 31 Aug 2020 13:45:05 GMT]]>Snakken om aktiesplit har været lidt stille det sidste lange stykke tid. Sidst var der ikke overbevisende stemning for det her på siden, men hvordan er sentiment nu? Apple og Tesla er gode eksempler på, at det kan betyde meget for psykologien om en aktie, når den bliver peberet. Tanker?

]]>https://dev.proinvestor.com/forum/post/10231035https://dev.proinvestor.com/forum/post/10231035Mon, 31 Aug 2020 13:45:05 GMT<![CDATA[Reply to Genmab — August 2020 on Mon, 31 Aug 2020 13:25:10 GMT]]>month-end

]]>https://dev.proinvestor.com/forum/post/10231032https://dev.proinvestor.com/forum/post/10231032Mon, 31 Aug 2020 13:25:10 GMT<![CDATA[Reply to Genmab — August 2020 on Mon, 31 Aug 2020 13:11:05 GMT]]>Kursen tog godt nok fart op ad her sidst på eftermiddagen. Er den i spekulanternes hænder lige i øjeblikket?

]]>https://dev.proinvestor.com/forum/post/10231038https://dev.proinvestor.com/forum/post/10231038Mon, 31 Aug 2020 13:11:05 GMT<![CDATA[Reply to Genmab — August 2020 on Mon, 31 Aug 2020 10:21:02 GMT]]>Ser ud til,generel lav omsætning med Bavarian som en undtagelse...

]]>https://dev.proinvestor.com/forum/post/10231030https://dev.proinvestor.com/forum/post/10231030Mon, 31 Aug 2020 10:21:02 GMT<![CDATA[Reply to Genmab — August 2020 on Mon, 31 Aug 2020 09:18:43 GMT]]>Meget, meget beskeden omsætning i dag ????

]]>https://dev.proinvestor.com/forum/post/10231029https://dev.proinvestor.com/forum/post/10231029Mon, 31 Aug 2020 09:18:43 GMT<![CDATA[Reply to Genmab — August 2020 on Mon, 31 Aug 2020 08:37:13 GMT]]>Hvad med Mayzent ?

]]>https://dev.proinvestor.com/forum/post/10231034https://dev.proinvestor.com/forum/post/10231034Mon, 31 Aug 2020 08:37:13 GMT<![CDATA[Reply to Genmab — August 2020 on Mon, 31 Aug 2020 06:17:35 GMT]]>Novartis har et MS stof på markedet der omsætter for små $3bn og som går af patent. Det forventes at de hurtigt vil skifte over til Kesimpta. Så det kan godt blive med raketfart de lægger fra land 🙂

]]>https://dev.proinvestor.com/forum/post/10231027https://dev.proinvestor.com/forum/post/10231027Mon, 31 Aug 2020 06:17:35 GMT<![CDATA[Reply to Genmab — August 2020 on Mon, 31 Aug 2020 04:36:49 GMT]]>Bliver spændende at se hvor hurtigt Kesimpta penetrerer markedet.

]]>https://dev.proinvestor.com/forum/post/10231026https://dev.proinvestor.com/forum/post/10231026Mon, 31 Aug 2020 04:36:49 GMT<![CDATA[Reply to Genmab — August 2020 on Mon, 31 Aug 2020 04:34:48 GMT]]>God morgen. :-).

]]>https://dev.proinvestor.com/forum/post/10231031https://dev.proinvestor.com/forum/post/10231031Mon, 31 Aug 2020 04:34:48 GMT<![CDATA[Reply to Genmab — August 2020 on Mon, 31 Aug 2020 04:14:19 GMT]]>Hvis Kesimpta kan dele markedet for nye patienter 50/50 med Ocrevus, så er det bedre end hvad der tidligere er estimeret. Vil være rigtig godt 🙂

]]>https://dev.proinvestor.com/forum/post/10231033https://dev.proinvestor.com/forum/post/10231033Mon, 31 Aug 2020 04:14:19 GMT<![CDATA[Reply to Genmab — August 2020 on Mon, 31 Aug 2020 04:14:12 GMT]]>Lyder godt Sukker 🙂

]]>https://dev.proinvestor.com/forum/post/10231025https://dev.proinvestor.com/forum/post/10231025Mon, 31 Aug 2020 04:14:12 GMT<![CDATA[Reply to Genmab — August 2020 on Mon, 31 Aug 2020 04:03:15 GMT]]>Tak Sukker. 🙂

]]>https://dev.proinvestor.com/forum/post/10231022https://dev.proinvestor.com/forum/post/10231022Mon, 31 Aug 2020 04:03:15 GMT<![CDATA[Reply to Genmab — August 2020 on Mon, 31 Aug 2020 03:38:49 GMT]]>https://www.firstwordpharma.com/node/1753296?tsid=1

]]>https://dev.proinvestor.com/forum/post/10231023https://dev.proinvestor.com/forum/post/10231023Mon, 31 Aug 2020 03:38:49 GMT<![CDATA[Reply to Genmab — August 2020 on Mon, 31 Aug 2020 03:38:39 GMT]]>KOL expects 50/50 split on patient preference between Kesimpta’s monthly injection and Ocrevus’ biannual infusion
Newly diagnosed patients will favour Kesimpta among the anti-CD20s because of the added control of self-administration

]]>https://dev.proinvestor.com/forum/post/10231019https://dev.proinvestor.com/forum/post/10231019Mon, 31 Aug 2020 03:38:39 GMT<![CDATA[Reply to Genmab — August 2020 on Mon, 31 Aug 2020 03:38:23 GMT]]>Summary points from expert feedback:

Uptake of Kesimpta will be brisk as it is a known mechanism and modality
Kesimpta’s monthly convenience will drain market share from older injectables
No clear difference on safety/efficacy for anti-CD20 mAbs like Kesimpta and Roche’s Ocrevus

]]>https://dev.proinvestor.com/forum/post/10231021https://dev.proinvestor.com/forum/post/10231021Mon, 31 Aug 2020 03:38:23 GMT<![CDATA[Reply to Genmab — August 2020 on Mon, 31 Aug 2020 03:38:21 GMT]]>KOL view Kesimpta

]]>https://dev.proinvestor.com/forum/post/10231028https://dev.proinvestor.com/forum/post/10231028Mon, 31 Aug 2020 03:38:21 GMT<![CDATA[Reply to Genmab — August 2020 on Mon, 31 Aug 2020 02:15:49 GMT]]>God morgen. 🙂

]]>https://dev.proinvestor.com/forum/post/10231024https://dev.proinvestor.com/forum/post/10231024Mon, 31 Aug 2020 02:15:49 GMT<![CDATA[Reply to Genmab — August 2020 on Mon, 31 Aug 2020 01:58:02 GMT]]>Go morgen.. ny dag.. 🙂

]]>https://dev.proinvestor.com/forum/post/10231018https://dev.proinvestor.com/forum/post/10231018Mon, 31 Aug 2020 01:58:02 GMT<![CDATA[Reply to Genmab — August 2020 on Sat, 29 Aug 2020 14:22:21 GMT]]>Det er modigt af GSK må man sige. Det forsøg tror jeg de taber på bivirkninger og PFS, men umiddelbar effekt på ORR, CR kan jeg ikke gætte udfaldet. Men vigtigt forsøg for JNJ/Genmab at vinde.

]]>https://dev.proinvestor.com/forum/post/10231020https://dev.proinvestor.com/forum/post/10231020Sat, 29 Aug 2020 14:22:21 GMT<![CDATA[Reply to Genmab — August 2020 on Sat, 29 Aug 2020 12:41:33 GMT]]>Ved ikke om dette fra 27 aug. på Clical trials ( DREAMM 7 ) study , har været vist ?? https://www.clinicaltrials.gov/ct2/show/NCT04246047?term=Darzalex&draw=4&rank=128

]]>https://dev.proinvestor.com/forum/post/10231017https://dev.proinvestor.com/forum/post/10231017Sat, 29 Aug 2020 12:41:33 GMT<![CDATA[Reply to Genmab — August 2020 on Sat, 29 Aug 2020 07:23:56 GMT]]>Optimal Approach to the Treatment of Young Adults with Acute Lymphoblastic Leukemia in 2020
https://www.sciencedirect.com/science/article/pii/S0037196320300275

]]>https://dev.proinvestor.com/forum/post/10231015https://dev.proinvestor.com/forum/post/10231015Sat, 29 Aug 2020 07:23:56 GMT